0B68 Cristofanilli, Massimo - Thomas Jefferson University - Thomas Jefferson University
mxc156

Massimo Cristofanilli, MD

Contact Dr. Cristofanilli

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib
  2. Gene expression profiles of inflammatory breast cancer: Correlation with response to neoadjuvant chemotherapy and metastasis-free survival
  3. A comparison of epidemiology, biology, and prognosis of inflammatory breast cancer in Japanese and US populations
  4. Presence of anaplastic lymphoma kinase in inflammatory breast cancer
  5. The Third International Inflammatory Breast Cancer Conference
  6. Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): A multicenter, double-blind, prospective trial
  7. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells
  8. Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma
  9. Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients
  10. Uncovering the molecular secrets of inflammatory breast cancer biology: An integrated analysis of three distinct affymetrix gene expression datasets
  11. Circulating tumor cells in metastatic colorectal cancer: Do we need an alternative cutoff?
  12. Circulating tumor DNA to monitor metastatic breast cancer [5]
  13. Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer
  14. Inflammatory breast cancer (IBC): Clues for targeted therapies
  15. Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy
  16. Genomic and expression analysis of microdissected inflammatory breast cancer
  17. Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients
  18. A chromosome-centric human proteome project (C-HPP) to characterize the sets of proteins encoded in chromosome 17
  19. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
  20. Prognostic value of EMT-circulating tumor cells in metastatic breast can-cer patients undergoing high-dose chemotherapy with autologous hematopoietic stem cell transplantation
0